Ras inhibitors
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
1. A method of treating lung cancer in a subject in need thereof, wherein the lung cancer comprises a K-Ras G12C mutation, the method comprising administering to the subject a therapeutically effective amount of a compound having the following structure:
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the lung cancer is non-small cell lung cancer.
3. The method of claim 1 , wherein the method comprises administering to the subject a therapeutically effective amount of the compound having the following structure:
4. A method of treating non-small cell lung cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound having the following structure:
or a pharmaceutically acceptable salt thereof.
5. The method of claim 4 , wherein the method comprises administering to the subject a therapeutically effective amount of the compound having the following structure:
6. The method of claim 2 , wherein the method comprises administering to the subject a therapeutically effective amount of the compound having the following structure:
7. The method of claim 2 , wherein the method comprises administering to the subject a therapeutically effective amount of the pharmaceutically acceptable salt of the compound having the following structure:
8. The method of claim 4 , wherein the method comprises administering to the subject a therapeutically effective amount of the pharmaceutically acceptable salt of the compound having the following structure: